-

Variantyx Expands Its Reproductive Health Offerings with Launch of a Direct Replacement for Chromosomal Microarray Analysis

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Variantyx, a leader in genomic precision medicine, today announced the launch of its IriSight™ CNV Analysis - a whole genome-based test for the detection of chromosomal abnormalities that correlate with clinical symptoms manifested in a fetus or a pregnancy, that may result in a genetic disorder or pregnancy loss.

“IriSight™ CNV Analysis provides the first true alternative to CMA,” said Dr. Allan J. Fisher, FACOG, FACMG, Variantyx Medical Director. “Because the entire genome is sequenced, a broader range of chromosomal abnormalities are detected by the test including aneuploidy, unbalanced rearrangements, inversions, deletions/duplications, copy number variants (CNVs), regions of homozygosity and possible uniparental disomy. Reflex options in cases with non-diagnostic outcomes offer the possibility of rapid and seamless, expanded whole genome analysis (WGS) of the already sequenced DNA that includes small sequence changes, mitochondrial variants, and short tandem repeat expansions.”

Chromosomal microarray analysis (CMA) is recommended by both the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) for use in prenatal diagnosis. Variantyx’s proprietary whole genome-based platform enables detection of a wider range of chromosomal abnormalities, not just matching but exceeding the capabilities of traditional CMA.

About Variantyx

Variantyx is an award-winning, technology-driven precision medicine company providing disruptive solutions for the genetic disorders, reproductive health, and precision oncology markets. The proprietary whole genome analysis platforms developed by Variantyx allow clinicians and patients to better understand a person’s genetic makeup, leading to unmatched diagnostic capabilities and improved personalized treatment recommendations. For more information, please visit www.variantyx.com.

Contacts

Haim Neerman
Haim.neerman@variantyx.com
(617) 209-2090

Variantyx


Release Versions

Contacts

Haim Neerman
Haim.neerman@variantyx.com
(617) 209-2090

More News From Variantyx

Variantyx Brings the First Combined Short- and Long-Read Whole Genome Sequencing Test to Market with Genomic Unity® 2.0

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Variantyx, a leading molecular diagnostics lab, today announced the launch of Genomic Unity® 2.0, a novel whole genome-based diagnostic test. This advanced test integrates traditional short-read genome sequencing with third-generation long-read genome sequencing, detecting genetic variants that are missed by other methodologies and improving diagnostic yield. Christine Stanley, PhD, FACMG, Chief Genomics & Compliance Officer at Variantyx, commented, “Geno...

Variantyx Secures $36M Investment As Testing Demand And Market Share Continues To Increase

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Variantyx, a leader in molecular diagnostics, announced today that it has secured an additional $36 million in funding from its portfolio of investors which includes Peregrine Ventures, Pitango HealthTech, New Era Capital Partners and Bosch Ventures. The company, a technology-driven provider of advanced genomic testing for genetic disorders, reproductive health and precision oncology markets has seen a rapid increase in test volumes in the first quarter of 20...

Expanded STR Detection Capability Enables Variantyx to Diagnose Additional Genetic Disorders

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Variantyx, a leader in genomic precision medicine, today announced that the set of short tandem repeat (STR) expansions detected by its Genomic Unity® line of whole genome-based tests has been expanded. With these additions, Variantyx becomes one of the first laboratories to offer testing for two recently characterized ataxia variants: the biallelic AAGGG expansion in RFC1 that causes cerebellar ataxia, neuropathy, vestibular areflexia syndrome (CANVAS) and t...
Back to Newsroom